PP147 Olaratumab With Doxorubicin For Advanced Soft Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462318002775
Abstract: Introduction: The National Institute for Health and Care Excellence (NICE) invited the manufacturer of olaratumab (Lartruvo®), Eli Lilly & Company Limited, to submit evidence for the clinical and cost effectiveness of this drug, in combination… read more here.
Keywords: advanced soft; soft tissue; cost; doxorubicin advanced ... See more keywords